
    
      A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of
      LT-02 (delayed release phosphatidylcholine granules; administered orally via 1.6 g BID for up
      to 12 weeks) in subjects with active ulcerative colitis who are refractory to a standard dose
      of oral mesalamine therapy. Refractory to mesalamine is defined as active disease despite
      receiving at least â‰¥ 2.4g mesalamine (or equivalent dose) for at least 8 weeks with or
      without rectal 5-ASA.
    
  